Overview
Subchorionic intervillositis (CHI), also known as subchorionic hemorrhage with inflammation, is a placental pathology characterized by an inflammatory infiltrate within the intervillous space of the placenta. This condition primarily involves an accumulation of macrophages, particularly CD68+ cells, alongside fibrin deposits that can lead to significant placental dysfunction. CHI is often associated with obstetric complications, including recurrent pregnancy loss, placental insufficiency, and adverse pregnancy outcomes. Understanding the pathophysiology, epidemiology, clinical presentation, and management strategies is crucial for optimizing outcomes in affected pregnancies.
Pathophysiology
CHI is histologically defined by an inflammatory infiltrate occupying at least 5% of the intervillous space, predominantly composed of CD68+ macrophages. These macrophages play a central role in the inflammatory response, often leading to syncytiotrophoblast necrosis due to the extensive fibrin deposition. The inflammatory process disrupts normal placental function, compromising nutrient and oxygen transfer to the fetus. The extent of macrophage infiltration and fibrin accumulation correlates directly with the severity of placental insufficiency, which can manifest as recurrent early pregnancy loss, intrauterine growth restriction, and preeclampsia. The underlying mechanisms may involve immune dysregulation, possibly exacerbated by factors such as autoimmune conditions, as evidenced by the higher prevalence of autoimmune diseases in women diagnosed with CHI [PMID:25028066].
Epidemiology
The incidence of CHI varies across different populations and study designs. A retrospective cohort study involving 1,273 frozen embryo transfer (FET) cycles revealed that the frequency of subchorionic hemorrhage (SCH), often associated with CHI, was significantly lower in natural cycles compared to programmed cycles. Specifically, the relative risk for SCH in natural cycles was 0.4 (95% CI: 0.27-0.78), with an odds ratio of 0.4 (95% CI: 0.23-0.75) compared to programmed cycles [PMID:32709380]. This suggests that certain aspects of cycle programming, such as hormonal manipulation, might influence the risk of developing SCH. Additionally, autoimmune diseases were identified in 29% of women diagnosed with CHI, indicating a potential link between immune dysregulation and the development of this condition [PMID:25028066]. Understanding these risk factors is essential for targeted screening and management strategies.
Clinical Presentation
The clinical presentation of CHI is often nonspecific in early pregnancy but can evolve into severe obstetric complications as the condition progresses. Patients may present with symptoms such as vaginal bleeding, pelvic pain, and in some cases, signs of placental insufficiency like fetal growth restriction or oligohydramnios. The severity of CHI, graded by the extent of macrophage infiltration (e.g., ≥50% of the intervillous space), correlates strongly with adverse outcomes. Higher grades of CHI are associated with greater placental damage and an increased risk of recurrent pregnancy loss, preterm birth, and preeclampsia [PMID:40178007]. Differential diagnoses should consider other causes of first trimester bleeding and placental abnormalities, such as placental abruption, placenta accreta, and other forms of placental insufficiency. Accurate diagnosis often relies on ultrasound findings, particularly the presence of subchorionic hemorrhage, and sometimes requires histopathological confirmation through placental examination post-delivery.
Diagnosis
Diagnosing CHI typically involves a combination of clinical assessment, imaging, and, when feasible, placental pathology. Clinical Assessment: Patients often present with first trimester bleeding and mild to moderate abdominal pain. Detailed history taking, including obstetric history and autoimmune disease status, is crucial. Imaging: Transvaginal ultrasound is the primary diagnostic tool, revealing subchorionic hemorrhage and sometimes demonstrating the extent of placental involvement. Characteristic findings include a hypoechoic area between the placenta and uterine wall. Histopathology: Definitive diagnosis often requires placental pathology, where histological examination confirms the presence of macrophage infiltration and fibrin deposits within the intervillous space [PMID:40178007]. Serial ultrasounds may be recommended to monitor the progression or resolution of the hemorrhage and associated placental changes.
Management
The management of CHI aims to mitigate placental damage and improve pregnancy outcomes. Medical Management: There is limited evidence supporting specific pharmacological interventions, but close monitoring and supportive care are essential. In cases where autoimmune conditions are implicated, managing underlying immune dysregulation may be beneficial. Surgical Interventions: Surgical management is generally reserved for severe cases with significant hemorrhage or complications like placenta accreta. Follow-Up: Regular ultrasounds (typically every 2-4 weeks) are recommended to assess placental position, hemorrhage size, and fetal well-being. In a multicenter study, targeted interventions led to a significant improvement in live birth rates from 32% to 67% in subsequent pregnancies, highlighting the importance of tailored management strategies [PMID:25028066]. Prognostic Considerations: Despite improved outcomes with active management, the risk of preterm delivery remains elevated at approximately 30%, necessitating close surveillance until term [PMID:25028066].
Key Recommendations
Complications
CHI carries significant risks that escalate with the severity of the inflammatory process. Higher grades of CHI, characterized by extensive macrophage infiltration (≥50% of the intervillious space), are strongly associated with severe placental damage. These complications include:
Understanding these potential complications guides the intensity and frequency of monitoring and intervention strategies.
Prognosis & Follow-up
The prognosis for pregnancies complicated by CHI varies widely depending on the severity of the condition and the effectiveness of management strategies. While targeted interventions can significantly improve live birth rates, as evidenced by the increase from 32% to 67% in subsequent pregnancies [PMID:25028066], the risk of preterm delivery remains a persistent concern, typically around 30% [PMID:25028066]. Long-term follow-up is crucial to monitor both maternal and neonatal outcomes post-delivery. Regular obstetric visits, including detailed ultrasounds and clinical assessments, should continue until term to ensure optimal fetal growth and to address any emerging complications promptly. Additionally, psychological support should be integrated into the follow-up plan to address the emotional toll of recurrent pregnancy complications.
References
1 Albersammer L, Leon J, Martinovic J, Dagobert J, Lebraud E, Bessières B et al.. Histologic and molecular features shared between antibody-mediated rejection of kidney allografts and chronic histiocytic intervillositis support common pathogenesis. The Journal of pathology 2025. link 2 Reich J, Blakemore JK, Grifo JA. Comparison of subchorionic hematoma in medicated or natural single euploid frozen embryo transfer cycles. Fertility and sterility 2020. link 3 Mekinian A, Costedoat-Chalumeau N, Masseau A, Botta A, Chudzinski A, Theulin A et al.. Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study. Autoimmunity 2015. link